Robert Huber (2011) - Proteasome and DegP Protease, Mechanisms and Drug Design

Robert Huber (2011)

Proteasome and DegP Protease, Mechanisms and Drug Design

Robert Huber (2011)

Proteasome and DegP Protease, Mechanisms and Drug Design

Abstract

Within cells or subcellular compartments misfolded and/or short-lived regulatory proteins are degraded by protease machines, cage-forming multi-subunit assemblages, the proteasome and HtrA/DegP. They are essential components in very complex regulatory pathways and interaction networks, the UPS (ubiquitin proteasome system) and the UPR (unfolded protein response), respectively. Their activity is precisely regulated by maturation from inactive precursors and sequestration of their proteolytic active sites within the particles (proteasome) and by activation of latent forms and oligomerization upon signaling by substrate (HtrA/DegP).
Both systems have proven (proteasome) or promise (HtrA/DegP) to be valuable targets for novel therapeutic drugs and antibiotics. The analyses of numerous crystal structures of the proteasome and the HtrA/DegP protein families complexed with ligands in conjunction with functional studies have provided a sound basis of structure-based design and development of many novel chemical entities as potential clinical candidates.
References:
Clausen, T., Kaiser, M., Huber, R. and Ehrmann, M. (2011). HTRA proteases: regulated proteolysis in protein quality control. Nature Reviews Molecular Cell Biology 12,152-162.
Gräwert, M. A., Gallastegui, N., Stein, M., Schmidt, B., Kloetzel, P. M., Huber, R. and Groll, M. (2011). Elucidation of the α-keto-aldehyde binding mechanism: A lead structure motif for proteasome inhibition. Angewandte Chemie Int. Ed. 50, 542-544.

Rate this content

 (<5 ratings)

Cite


Specify width: px

Share

Rate this content

 (<5 ratings)

Cite


Specify width: px

Share


Related Content